Altered mucosal and plasma polyunsaturated fatty acids, oxylipins, and endocannabinoids profiles in Crohn's disease.

[1]  L. Steardo,et al.  N-Palmitoyl-D-Glucosamine Inhibits TLR-4/NLRP3 and Improves DNBS-Induced Colon Inflammation through a PPAR-α-Dependent Mechanism , 2022, Biomolecules.

[2]  M. Szczuko,et al.  Involvement of Proinflammatory Arachidonic Acid (ARA) Derivatives in Crohn’s Disease (CD) and Ulcerative Colitis (UC) , 2022, Journal of clinical medicine.

[3]  R. Scott,et al.  Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease – A Systematic Review , 2021, Frontiers in Immunology.

[4]  U. Das.  Essential Fatty Acids and Their Metabolites in the Pathobiology of Inflammation and Its Resolution , 2021, Biomolecules.

[5]  P. Calder,et al.  Omega-3 Polyunsaturated Fatty Acids and the Intestinal Epithelium—A Review , 2021, Foods.

[6]  Philip C. Calder.  Eicosanoids. , 2020, Essays in biochemistry.

[7]  M. Hersberger,et al.  Nutritional Lipids and Mucosal Inflammation. , 2020, Molecular nutrition & food research.

[8]  S. Ng,et al.  The epidemiology of inflammatory bowel disease: East meets west , 2019, Journal of gastroenterology and hepatology.

[9]  L. Stassen,et al.  ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[10]  R. Witkamp,et al.  The role of n-3 PUFA-derived fatty acid derivatives and their oxygenated metabolites in the modulation of inflammation. , 2019, Prostaglandins & other lipid mediators.

[11]  Elizabeth A. Scoville,et al.  Serum Polyunsaturated Fatty Acids Correlate with Serum Cytokines and Clinical Disease Activity in Crohn’s Disease , 2019, Scientific Reports.

[12]  N. Ferreirós,et al.  Members of the endocannabinoid system are distinctly regulated in inflammatory bowel disease and colorectal cancer , 2019, Scientific Reports.

[13]  A. Nusrat,et al.  Saving Problematic Mucosae: SPMs in Intestinal Mucosal Inflammation and Repair. , 2019, Trends in molecular medicine.

[14]  T. Moritz,et al.  A Quantitative Analysis of Colonic Mucosal Oxylipins and Endocannabinoids in Treatment-Naïve and Deep Remission Ulcerative Colitis Patients and the Potential Link With Cytokine Gene Expression , 2018, Inflammatory bowel diseases.

[15]  R. Schicho,et al.  Cellular localization and regulation of receptors and enzymes of the endocannabinoid system in intestinal and systemic inflammation , 2018, Histochemistry and Cell Biology.

[16]  Sakura Masuko,et al.  Production of lipid mediators across different disease stages of dextran sodium sulfate-induced colitis in mice[S] , 2018, Journal of Lipid Research.

[17]  Valerio Chiurchiù,et al.  Bioactive Lipids and Chronic Inflammation: Managing the Fire Within , 2018, Front. Immunol..

[18]  S. Danese,et al.  Actors and Factors in the Resolution of Intestinal Inflammation: Lipid Mediators As a New Approach to Therapy in Inflammatory Bowel Diseases , 2017, Front. Immunol..

[19]  A. Das,et al.  Anti-inflammatory ω-3 endocannabinoid epoxides , 2017, Proceedings of the National Academy of Sciences.

[20]  L. Peyrin-Biroulet,et al.  Crohn's disease , 2017, The Lancet.

[21]  M. Perretti,et al.  Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection , 2017, Proceedings of the National Academy of Sciences.

[22]  R. Reifen,et al.  α-Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease. , 2015, The Journal of nutritional biochemistry.

[23]  B. Savaş,et al.  Impact of colonic mucosal lipoxin A4 synthesis capacity on healing in rats with dextran sodium sulfate-induced colitis. , 2015, Prostaglandins & other lipid mediators.

[24]  Takao Shimizu,et al.  A comprehensive quantification method for eicosanoids and related compounds by using liquid chromatography/mass spectrometry with high speed continuous ionization polarity switching. , 2015, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[25]  P. Calder,et al.  Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity. , 2014, Journal of Crohn's & colitis.

[26]  Lauren L Nicotra,et al.  Prostaglandin ethanolamides attenuate damage in a human explant colitis model. , 2013, Prostaglandins & other lipid mediators.

[27]  A. Bitto,et al.  Flavocoxid, a dual inhibitor of COX-2 and 5-LOX of natural origin, attenuates the inflammatory response and protects mice from sepsis , 2012, Critical Care.

[28]  A. Vanoli,et al.  The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease , 2011, Mucosal Immunology.

[29]  C. Serhan.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? , 2010, The American journal of pathology.

[30]  Penny A. Johnson,et al.  Colonic expression of leukotriene‐pathway enzymes in inflammatory bowel diseases , 2007, Inflammatory bowel diseases.

[31]  V. Di Marzo,et al.  Endocannabinoid overactivity and intestinal inflammation , 2006, Gut.

[32]  Jianan Ren,et al.  Regulated Spatial Distribution of Cyclooxygenases and Lipoxygenases in Crohn's Ulcer , 2006, Mediators of inflammation.

[33]  M. Valenti,et al.  Up‐regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Thanos Athanasiou,et al.  Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. , 2005, The Annals of thoracic surgery.

[35]  I. Singer,et al.  Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. , 1998, Gastroenterology.

[36]  T. Toyota,et al.  Altered leukotriene B4 metabolism in colonic mucosa with inflammatory bowel disease. , 1995, Scandinavian journal of gastroenterology.

[37]  R. Eliakim,et al.  Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis. , 1992, Scandinavian journal of gastroenterology.

[38]  C. Smith,et al.  Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. , 1991, Gut.

[39]  R. F. Harvey,et al.  A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.